EPHA2 Expression

CI-VAR-00001060Explore in graph →CIViC 5255

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Uterine Neoplasm1
EPHA2 Expression	Dasatinib + TrametinibCombination	Predictive	D	Supports Sensitivity Response	2	submitted	EID12576 In a preclinical study of uterine cancer cell lines resistant to EphA2 inhibitors (HEC-1A, Ishikawa, RL-95), EphA2-positive cells treated with the MEK inhibitor trametinib restored sensitivity to dasa… (full text at CIViC) PMID 34391578 · Wu et al., 2021 · Open in CIViC	civic
Uterine Corpus Endometrial Carcinoma1unmapped disease
EPHA2 Expression	Dasatinib + TrametinibCombination	Predictive	C	Supports Sensitivity Response	2	submitted

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.